Schizophrenia/Psychosis

After 30+ years of clinical experience with clozapine, it is time for professional psychiatry to demand an end to this discriminatory clozapine REMS program.

The vice president of Clinical Development and Medical Affairs, Mental Health at Boehringer Ingelheim shares why it is such an unprecedented moment for schizophrenia research.

Cobenfy: Only the first in a new upcoming class of antipsychotics.

While there is still a lot to learn about Cobenfy, here's why it marks a historic moment in the treatment of schizophrenia.

Multiple sites are now enrolling participants in a phase 2 clinical trial to evaluate SPG302, the first synaptic regenerative therapy for schizophrenia.

The first-in-class muscarinic agonist Cobenfy, formerly known as KarXT, was just approved by the FDA to treat schizophrenia in adults. Are you ready to discuss it with patients and caregivers?

Does reduced blood monitoring impact the detection of hematological abnormalities in clozapine-treated patients? Researchers performed a chart review study from the COVID-10 pandemic.

The US Food and Drug Administration approves Cobenfy (KarXT), the first new agent with a novel mechanism of action for schizophrenia more than 50 years.

New data informs clinicians of how best to switch patients from a once-monthly subcutaneous injection of RBP-7000 (Perseris) to risperidone (Uzedy), an extended-release injectable suspension of risperidone for subcutaneous use every 1 or 2 months for the treatment of schizophrenia in adults.

Check out new positive efficacy, safety, and tolerability results from the phase 3 SOLARIS trial evaluating TEV-‘749 in adult patients diagnosed with schizophrenia.

How comfortable do you feel in your knowledge of this type of treatment?

Later this month, the FDA will vote on KarXT, a novel muscarinic acetylcholine receptor agonist.

Why are experts excited about KarXT, a novel muscarinic acetylcholine receptor agonist that, if approved, is poised to revolutionize schizophrenia treatment?

Assisted outpatient treatment is not intended to replace comprehensive, easy-to-access, voluntary treatment. Here's why we need it, according to one expert.

The PDUFA date for KarXT for schizophrenia is September 26, 2024. Here’s what one expert thinks of this potential treatment.

A new study of adult emergency department admissions found that individuals taking high doses of amphetamine—like Adderall—have a 5-fold increased risk for developing psychosis or mania.

Neurosyphilis may occur during any stage of syphilis. Learn more about this diagnosis via case study example here.

Antidepressants posed "negligible" risk of inducing mania in bipolar depression, in a target trial emulation with a larger cohort than in RCTs that have assessed this effect.

Racism is not usually considered a psychotic symptom and therefore it is not often considered in the diagnosis of schizophrenia.

Sleep and suicide? Researchers investigated improvement in insomnia as a pathway underlying the antisuicidal properties of clozapine.

The first investigational, oral, muscarinic M4 selective agonist in development for the treatment of schizophrenia sees positive phase 2 results in the lowest tested dose.

A review and meta-analysis of antipsychotic dose-response literature prompts a proposal for lower maximum target doses.

Cannabis use during adolescence can profoundly impact brain development.

Evidence indicates that children and adolescents with ADHD have a more than 4-fold increased risk of schizophrenia spectrum and other psychotic disorders in adulthood compared with the general population.

Check out these exciting updates from the recent RISE study on TV-46000, a subcutaneous long-acting injectable antipsychotic formulation of risperidone.

The US Food and Drug Administration has approved Erzofri, a paliperidone palmitate extended-release injectable suspension for the treatment of adults with schizophrenia and schizoaffective disorder.

In this CME article, review management of several clozapine-related adverse effects and outline considerations when addressing inadequate positive symptom response to clozapine.

How can you differentiate between non-idiosyncratic prejudice and psychosis when a patient presents exhibiting discriminatory behavior? Learn more here.

This book documents one clinician’s personal experiences with schizophrenia, insurance difficulties, and more.